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A B S T R A C T
Objective: The aim of this study was to evaluate the eﬀect of the co-administration of vitamin D and omega-3
fatty acid on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome (PCOS).
Methods: This randomized, double-blinded, placebo-controlled clinical trial was conducted on 60 subjects, aged
18–40 years old with PCOS. Subjects were randomly allocated to take either 50,000 IU vitamin D every 2 weeks
plus 2000mg/day omega-3 fatty acid from ﬁsh oil (n=30) or placebo (n=30) for 12 weeks. Gene expression
analysis of inﬂammatory cytokines was conducted on peripheral blood mononuclear cells (PBMCs) of PCOS
women using RT-PCR method.
Results: Vitamin D and omega -3 fatty acid co-supplementation signiﬁcantly decreased serum total testosterone
levels (−0.2 ± 0.5 vs.+ 0.1 ± 0.4 ng/mL, P=0.02) compared with the placebo. In addition, vitamin D and
omega-3 fatty acid co-supplementation resulted in a signiﬁcant improvement in beck depression inventory
(−1.4 ± 1.6 vs. −0.5 ± 0.6, P=0.01), general health questionnaire scores (−4.5 ± 4.3 vs. −1.9 ± 2.3,
P=0.005) and depression anxiety and stress scale scores (−5.0 ± 5.1 vs. −2.3 ± 3.5, P=0.01) compared
with the placebo. Additionally, vitamin D and omega-3 fatty acid co-administration signiﬁcantly decreased
serum high-sensitivity C-reactive protein (hs-CRP) (−1.2 ± 1.9 vs.+ 0.1 ± 0.7mg/L, P=0.001) and mal-
ondialdehyde (MDA) levels (−0.4 ± 0.4 vs.+ 0.2 ± 0.6 µmol/L, P<0.001), and signiﬁcantly increased
plasma total antioxidant capacity (TAC) levels (+ 114.6 ± 122.2 vs. -2.4 ± 168.2mmol/L, P=0.003) com-
pared with the placebo. Results of RT-PCR demonstrated that vitamin D and omega-3 fatty acid co-supple-
mentation signiﬁcantly downregulated gene expression of interleukin-1 (IL-1) (P=0.03), and upregulated
vascular endothelial growth factor (VEGF) (P=0.004) in PBMCs of subjects with PCOS, when compared with
placebo.
Conclusions: Overall, the co-administration of vitamin D and omega-3 fatty acid for 12 weeks had beneﬁcial
eﬀects on mental health parameters, serum total testosterone, hs-CRP, plasma TAC and MDA levels, and gene
expression of IL-1 and VEGF among women with PCOS.
1. Introduction
Polycystic ovary syndrome (PCOS) occurs in 6% to 10% of women
in reproductive age (Bozdag et al., 2016) and is characterized by hy-
perandrogenism, menstrual dysfunction, impaired fertility and
polycystic ovaries (Setji and Brown, 2014). This common endocrine
disorder is also associated with dyslipidemia (Bargiota and Diamanti-
Kandarakis, 2012), inﬂammation (Escobar-Morreale et al., 2011; Kelly
et al., 2001), oxidative stress, insulin resistance and hypertension
(Goodarzi et al., 2011), all risk factors for metabolic syndrome, type 2
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diabetes mellitus (T2DM) and cardiovascular diseases (Krul-Poel et al.,
2013). In addition, PCOS increases the risk of mental illnesses in-
cluding, depression and anxiety (Cooney and Dokras, 2017). Due to the
multitude of associated comorbidities and complications with PCOS,
there is a costly multidisciplinary approach of care ranging from en-
docrinologists, gynecologists, psychiatrists to dermatologists.
Insulin resistance subsequent to abdominal obesity might play an
important role in the pathogenesis of PCOS. This can result in ovarian
and adrenal hyperandrogenism which leads to an increased accumu-
lation of fat in the body and, ultimately, a vicious cycle of higher fat and
higher androgen in the development of PCOS complications (Gambineri
et al., 2002; Nasiri et al., 2015). This correlation might be mediated
through the stimulation of oxidative stress pathway, triggered by fat
accumulation (Vincent et al., 2007). Moreover, because of excess an-
drogen and adipose tissue malfunction, chronic inﬂammation might be
involved in the pathogenesis of metabolic and reproductive dysfunc-
tions of PCOS (Spritzer et al., 2015). Impaired angiogenesis and en-
dothelial dysfunction are also correlated with PCOS (Spritzer et al.,
2015). Ovaries with PCOS upregulate vascular endothelial growth
factor (VEGF) associated with increased vascularity (Pan et al., 2002;
Tal et al., 2015). Intriguing recent evidence further suggests that PCOS
might be associated with vitamin D. Genes involved in vitamin D level
regulation are associated with glucose and lipid metabolism and blood
pressure control (Wehr et al., 2011). Vitamin D may also aﬀect in-
ﬂammation and oxidative stress through its impact on preventing da-
maged DNA propagation in cellular level (Nair-Shalliker et al., 2012).
A combination of diﬀerent nutrients and improving overall nutri-
tional status might have beneﬁcial eﬀects for patients suﬀering from
PCOS (Maktabi et al., 2018), for instance, showed that a combination of
magnesium, zinc, calcium and vitamin D for 12 weeks inﬂuenced
markers of inﬂammation, oxidative stress and impaired hormones in
women with PCOS. Yet, Garg et al. (2015) showed that 4000 IU/day
vitamin D for six months did not beneﬁt insulin secretion and cardio-
vascular risk factors in women suﬀering from PCOS. We hypothesized
that with co-administration of vitamin D and omega-3, and the re-
sulting immunomodulatory and anti-inﬂammatory impacts, that the
hormonal proﬁle, metabolic abnormalities, mental illness, inﬂamma-
tion and endothelial dysfunction might be improved in women with
PCOS. To our knowledge, this is the ﬁrst randomized clinical trial to
assess the eﬀects of a combined vitamin D and omega-3 treatment on
clinical, metabolic and genetic parameters in women with PCOS.
2. Materials and methods
2.1. Trial design and subjects
This randomized double-blinded, placebo-controlled trial registered
in the Iranian website for registration of clinical trials (http://
www.irct.ir: http://www.irct.ir/user/trial/6144/view) and followed
the Declaration of Helsinki and Good Clinical Practice guidelines. This
trial was conducted among 60 women with PCOS, diagnosed based on
the Rotterdam criteria (Rotterdam ESHRE/ASRM-Sponsored
PCOS Consensus Workshop Group, 2004), aged 18–40 years old whom
referred to the Kosar Clinic in Arak, Iran, between February and Oc-
tober 2017. The study protocol was approved by the Ethics Committee
of Arak University of Medical Sciences (AUMS). Written informed
consent was obtained from all participants prior to the intervention.
Exclusion criteria included pregnancy, adrenal hyperplasia, androgen-
secreting tumors, hyperprolactinemia, thyroid dysfunction, diabetes or
impaired glucose tolerance at enrollment.
2.2. Supplementation
Subjects were randomized to take either vitamin D (50,000 IU bi-
weekly) plus 2 g/day omega-3 fatty acids from ﬁsh oil or placebo
(n=30 each group) for 12 weeks. Vitamin D, omega-3 fatty acids and
the placebo were manufactured by Zahravi Pharmaceutical Company
(Tabriz, Iran). The appearance of the placebo, vitamin D3 and omega 3
capsules, such as color, shape, size, and packaging, were totally similar.
The compliance rate was assessed by measuring serum 25(OH) vitamin
D levels, using the enzyme-linked immunosorbent assay (ELISA)
method. To evaluate confounding eﬀects of dietary intake and physical
activity, all subjects completed 3-day food records (once during the
weekend and on two weekdays) and three physical activity records as
metabolic equivalents at weeks 0, 3, 6, 9 and 12 of the intervention.
Daily macro- and micro-nutrient intakes were calculated by nutritionist
IV software (First Databank, San Bruno, CA).
2.3. Anthropometric measures
A trained midwife took anthropometric measurements in the clinic
at baseline and the end of the intervention. Height and weight (Seca,
Hamburg, Germany) were measured light clothing with shoes removed.
Body mass index (BMI) was calculated as weight (in kilograms) divided
by height (in meters) squared.
2.4. Clinical measures
Clinical assessments included hirsutism and its changes over time,
using a mFG scoring system (Hatch et al., 1981).
Mental health was judged with beck depression inventory (BDI),
general health questionnaire-28 (GHQ-28) and depression anxiety and
stress scale (DASS) at baseline and week 12 of the intervention. BDI is a
self-compiled questionnaire of 21 items in multiple choice format
(Beck et al., 1961). The GHQ-28 comprises 28-item consisting of 4
subscales (Goldberg and Hillier, 1979). DASS questionnaire consists of
three 14-item self-report scales that measure depression, anxiety and
stress (Crawford and Henry, 2004).
2.5. Biochemical measures
Fasting blood samples (15mL) were collected at baseline and the
end of the intervention at Arak reference laboratory. Serum 25-hydro-
xyvitamin D levels were measured using an ELISA kit (IDS, Boldon, UK)
with inter- and intra-assay coeﬃcient of variations (CVs) of lower than
7%. Serum total testosterone with inter- and intra-assay CVs of 4.4 to
6.2%, sex hormone-binding globulin (SHBG) with inter- and intra-assay
CVs of 3.7–5.6% and DHEAS concentrations with inter- and intra-assay
CVs of 4.0–6.3% were measured using commercial validated kits
(DiaMetra, Milano, Italy). Free androgen index (FAI) was calculated as
the percentage of total testosterone/SHBG. Serum high sensitivity C-
reactive protein (hs-CRP) concentrations were quantiﬁed using com-
mercial ELISA kit (LDN, Nordhorn, Germany) with inter- and intra-
assay CVs of lower than 7%. Plasma NO levels were measured using
Griess method (Tatsch et al., 2011). Plasma total antioxidant capacity
(TAC) concentrations were determined using the method of ferric re-
duction antioxidant power developed by Benzie and Strain (Benzie and
Strain, 1996). Total glutathione (GSH) and malondialdehyde (MDA)
concentrations also were measured using Beutler method (Beutler and
Gelbart, 1985) and thiobarbituric acid reactive substances spectro-
photometric test, respectively (Janero, 1990). CVs for plasma TAC, GSH
and MDA were less than 5%.
2.6. Isolation of lymphocyte cells
Lymphocyte cells were extracted from blood samples using a 50%
percoll (Sigma-Aldrich, Dorset, UK). Samples were taken for cell count
and viability testing by trypan blue, RNA and DNA extraction
(Dunkley et al., 2008).
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2.7. RNA extraction and real-time PCR (RT-PCR)
RNX-plus kit (Cinnacolon, Tehran, Iran) was used to extract RNA.
RNA suspension was frozen in− 20 °C until cDNA preparation.
Following the extraction of total RNAs from each sample, RNA quan-
tiﬁcation was performed using UV spectrophotometer. The OD 260/280
ratio of each sample was intended between 1.7 and 2.1 (Dunkley et al.,
2008). The isolated RNA was reverse transcribed to cDNA library using
moloney murine leukemia virus reverse transcriptase. Gene expression
of interleukin-1 (IL-1), IL-8 and TNF-α, transforming growth factor beta
(TGF-β) and vascular endothelial growth factor were determined by
quantitative RT-PCR on peripheral blood mononuclear cells (PBMCs),
using the LightCycler technology (Roche Diagnostics, Rotkreuz, Swit-
zerland) with SYBR green detection and Amplicon Kit (Table 1). Gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were used
as housekeeping gene. To design primers, we used Primer Express
Software (Applied Biosystems, Foster City) and Beacon designer soft-
ware (Takaposizt, Tehran, Iran). Relative transcription levels were
calculated by the method of Pﬀaﬁ or 2−ΔΔCT.
2.8. Sample size calculation
To determine the sample size for this clinical trial, we considered
type one error (α) of 0.05 and type two error (β) of 0.20 and the power
of 80%. Based on a previous study (Garg et al., 2015), we used 0.11 ng/
mL as SD and 0.09 ng/mL as the mean diﬀerence (d) of total testos-
terone concentration as the primary variable. Accordingly, 25 subjects
were required in each group. Considering a dropout of 5 subjects per
group, we calculated sample size as 30 subjects per treatment group.
2.9. Randomization
Randomization assignment was performed using computer-gener-
ated random numbers. Randomization and allocation concealment
were conducted by the researchers and subjects and were carried out by
a trained staﬀ member at the gynecology clinic. Another person, who
was not involved in the trial and not aware of random sequences, as-
signed the subjects to the numbered bottles of capsules.
2.10. Statistical methods
The Kolmogorov–Smirnov test was used to determine whether study
variables were normally. Analyses were performed based on an inten-
tion-to-treat (ITT) principle. Independent-samples t tests were used to
detect the diﬀerences in anthropometric measures, macro- and micro-
nutrient intakes between two intervention groups. To determine the
eﬀects of vitamin D and omega-3 fatty acid co-supplementation on
clinical and metabolic parameters, we used one-way repeated measures
analysis of variance. To compare the eﬀects of vitamin D and omega-3
fatty acid co-supplementation on gene expression related to in-
ﬂammation, independent-samples t tests were used. Using general
linear models and analysis of covariance (ANCOVA), we adjusted for
the baseline values of age and BMI. The P-values of< 0.05 were con-
sidered statistically signiﬁcant. All statistical analyses were conducted
using the Statistical Package for Social Science version 18 (SPSS Inc.,
Chicago, Illinois, USA).
3. Results
Initially, 69 subjects were screened; of whom 9 subjects were ex-
cluded due to lack of our inclusion criteria. In the current study, 4
subjects in the supplemented group and 4 in the placebo group were
dropped out for personal reasons (Fig. 1). Finally, 52 participants
[supplements (n=26) and placebo (n=26)] completed the trial.
However, all 60 participants were included in the ﬁnal analysis based
on the ITT principle.
Anthropometric measures including mean age, height, weight and
BMI were not statistically diﬀerent between the two intervention
groups at both baseline and end-of-trial (Table 2).
Based on the 3-day dietary records collected at baseline, end-of-trial
and throughout the study, there was no signiﬁcant diﬀerence in mean
dietary macro- and micro-nutrient intakes between the two interven-
tion groups (Data not shown).
Vitamin D and omega− 3 fatty acid co-supplementation signiﬁcantly
decreased serum total testosterone levels (− 0.2 ± 0.5 vs.+0.1 ±
0.4 ng/mL, P=0.02) compared with the placebo (Table 3). In addition,
vitamin D and omega− 3 fatty acid co-supplementation resulted in a
signiﬁcant improvement in BDI (− 1.4 ± 1.6 vs.− 0.5 ± 0.6,
P=0.01), GHQ (− 4.5 ± 4.3 vs.− 1.9 ± 2.3, P=0.005) and DASS
scores (− 5.0 ± 5.1 vs.− 2.3 ± 3.5, P=0.01) compared with the pla-
cebo. Additionally, vitamin D and omega-3 fatty acid co-administration
signiﬁcantly decreased serum hs-CRP levels (− 1.2 ± 1.9 vs.+0.1 ±
0.7mg/L, P=0.001) and MDA levels (− 0.4 ± 0.4 vs.+0.2 ±
0.6 µmol/L, P<0.001), and signiﬁcantly increased plasma TAC
(+114.6 ± 122.2 vs.− 2.4 ± 168.2mmol/L, P=0.003) compared
with the placebo. We did not observe any signiﬁcant eﬀect of combined
vitamin D and omega-3 fatty acid on other hormonal proﬁles, plasma NO
and GSH.
Analyses were controlled for baseline characteristics including age,
BMI and baseline values of each biochemical parameters were sig-
niﬁcantly diﬀerent between treatment groups and ﬁndings remained
unchanged (Table 4).
RT-PCR results demonstrated that vitamin D and omega-3 fatty acid
co-supplementation signiﬁcantly downregulated gene expression of IL-
1 (P=0.03), and upregulated VEGF (P=0.004) in PBMCs of women
with PCOS, when compared to placebo (Figs. 2 and 3). There was no
Table 1
Speciﬁc primers used for real-time quantitative PCR.
Gene Primer Product
size (bp)
Annealing
temperature (C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
IL-1 F: GCTTCTCTCTGGTCCTTGG 174 56
R: AGGGCAGGGTAGAGAAGAG
IL-8 F: GCAGAGGGTTGTGGAGAAGT 150 56
R: ACCCTACAACAGACCCACAC
TNF-α F: GTCAACCTCCTCTCTGCCAT 188 52
R: CCAAAGTAGACCTGCCCAGA
TGF-β F: TTGAGACTTTTCCGTTGCCG 227 56
R: CGAGGTCTGGGGAAAAGTCT
VEGF F: CTTCTGAGTTGCCCAGGAGA 216 54
R: CTCACACACACACAACCAGG
GAPDH, glyceraldehyde-3-Phosphate dehydrogenase; IL-1, interleukin-1; IL-8,
interleukin-8; TNF-α, tumor necrosis factor alpha; TGF-β, transforming growth
factor beta; VEGF, vascular endothelial growth factor.
Table 2
General characteristics of study participants.
Placebo group
(n=30)
Vitamin D plus omega-3
group (n=30)
P1
Age (y) 25.1 ± 3.7 26.8 ± 4.4 0.12
Height (cm) 163.9 ± 5.7 163.5 ± 4.4 0.80
Weight at study baseline (kg) 72.4 ± 17.1 73.1 ± 10.0 0.85
Weight at end-of-trial (kg) 72.2 ± 17.2 72.5 ± 10.0 0.93
Weight change (kg) −0.2 ± 1.1 −0.6 ± 1.1 0.21
BMI at study baseline (kg/m2) 27.1 ± 7.0 27.4 ± 3.9 0.85
BMI at end-of-trial (kg/m2) 27.0 ± 7.1 27.1 ± 3.8 0.92
BMI change (kg/m2) −0.1 ± 0.4 −0.2 ± 0.4 0.22
Data are means ± SDs.
1 Obtained from independent t-test.
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signiﬁcant eﬀect of vitamin D and omega-3 fatty acid co-supple-
mentation on gene expression of IL-8, TNF-α and TGF-β.
4. Discussion
Current study demonstrates that 12 weeks of combined vitamin D
and omega-3 fatty acid signiﬁcantly alleviates depression and anxiety
symptoms women with PCOS suﬀer from, and improves mental health
status. It also decreases androgen levels helping to attenuate related
symptoms. Moreover, co-administration of vitamin D and omega-3 fatty
acid improves total antioxidant capacity and reduces inﬂammation in
the body, the mainstream of PCOS comorbidities and complication.
Interestingly, this combination upregulates gene expression of VEGF
moderately which helps better tissue oxygenation and boosting immune
system. So, the addition of omega-3 fatty acid to vitamin D might
promote its anti-inﬂammatory and immunomodulatory eﬀects, which
are beneﬁcial for a complex of metabolic abnormalities in PCOS.
4.1. Eﬀect on hormonal measures
The major pathophysiology of PCOS is the excessive levels of an-
drogens in the body. More than 75% of women with PCOS have high
Table 3
Hormonal status and inﬂammatory and oxidative stress markers at baseline and after the 12-week intervention in subjects with polycystic ovary syndrome.
Placebo group (n=30) Vitamin D plus omega-3 group (n=30) P1
Baseline End-of-trial Change Baseline End-of-trial Change
25-OH-vitamin D (ng/mL) 12.4 ± 2.7 12.7 ± 3.2 0.3 ± 1.1 12.1 ± 3.1 21.9 ± 6.3 9.8 ± 5.1 <0.001
Total testosterone (ng/mL) 1.2 ± 0.7 1.3 ± 0.7 0.1 ± 0.4 1.4 ± 0.7 1.2 ± 0.6 −0.2 ± 0.5 0.02
SHBG (nmol/L) 43.5 ± 16.2 47.8 ± 26.8 4.4 ± 21.4 46.7 ± 22.9 52.7 ± 39.3 6.0 ± 24.5 0.78
FAI% 0.12 ± 0.12 0.11 ± 0.07 −0.01 ± 0.07 0.13 ± 0.13 0.11 ± 0.07 −0.02 ± 0.10 0.76
mF-G scores 11.3 ± 4.3 11.1 ± 4.1 −0.2 ± 0.6 11.8 ± 3.4 11.4 ± 3.2 −0.4 ± 0.5 0.15
BDI total scores 11.4 ± 4.3 10.8 ± 4.2 −0.5 ± 0.6 10.8 ± 5.8 9.4 ± 5.6 −1.4 ± 1.6 0.01
GHQ scores 51.1 ± 8.4 49.5 ± 8.2 −1.9 ± 2.3 47.2 ± 11.4 42.7 ± 10.9 −4.5 ± 4.3 0.005
DASS scores 103.4 ± 19.2 101.2 ± 18.8 −2.3 ± 3.5 101.3 ± 20.1 96.2 ± 19.2 −5.0 ± 5.1 0.01
hs-CRP (mg/L) 3.9 ± 1.5 4.0 ± 1.5 0.1 ± 0.7 4.2 ± 2.2 3.0 ± 1.7 −1.2 ± 1.9 0.001
NO (μmol/L) 44.6 ± 6.1 43.1 ± 8.4 −1.5 ± 6.3 39.2 ± 2.1 39.5 ± 3.1 0.3 ± 3.9 0.17
TAC (mmol/L) 946.7 ± 104.9 944.3 ± 174.7 −2.4 ± 168.2 996.0 ± 111.3 1110.6 ± 144.2 114.6 ± 122.2 0.003
GSH (μmol/L) 526.4 ± 74.7 550.6 ± 124.1 24.3 ± 116.4 559.1 ± 89.9 543.6 ± 88.2 −15.5 ± 85.8 0.13
MDA (μmol/L) 2.8 ± 0.5 3.0 ± 0.7 0.2 ± 0.6 2.9 ± 0.5 2.5 ± 0.3 −0.4 ± 0.4 <0.001
All values are means ± SDs.
BDI, beck depression inventory; DASS, depression anxiety and stress scale; GHQ, general health questionnaire; GSH, total glutathione; FAI, free androgen index; hs-
CRP, high-sensitivity C-reactive protein; mF-G, modiﬁed Ferriman Gallwey; MDA, malondialdehyde; NO, nitric oxide; SHBG, sex hormone-binding globulin; TAC,
total antioxidant capacity.
1 P values represent the time× group interaction (computed by analysis of the one-way repeated measures ANOVA).
Fig. 1. Summary of patient ﬂow diagram.
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androgens level free testosterone (Hahn et al., 2006). Current evidence
is suggesting that low serum vitamin D levels are associated with high
androgen levels. An inverse relationship has been reported between
serum 25(OH)D levels and testosterone, DHEAS and SHBG among
women with PCOS (Hahn et al., 2006; Velija-Asimi, 2014). We found
that vitamin D and omega-3 fatty acid co-supplementation for 12 weeks
signiﬁcantly decreased total testosterone levels among women with
PCOS, but did not aﬀect other hormonal measures. Consistent with our
ﬁndings, the meta-analysis conducted by Azadi-Yazdi et al. (2017)
showed signiﬁcant reduction in serum total testosterone, and not free
testosterone level, following vitamin D supplementation in PCOS pa-
tients. Vitamin D might play an important role in glucose metabolism
by inducing insulin synthesis and release, and increasing insulin re-
ceptor expression, so vitamin D deﬁciency possibly contributes to the
development of insulin resistance (Teegarden and Donkin, 2009). The
eﬀect of vitamin D deﬁciency on hormonal measures in PCOS might be
related to insulin resistance, which increases hyperandrogenism
through insulin increasing ovarian production of androgens and redu-
cing SHBG production. Moreover, a few vitamin D receptors gene
polymorphisms might be associated with lower insulin resistance and
lower testosterone levels (Plymate et al., 1988; Wehr et al., 2011).
Adding omega-3 to vitamin D supplementation might promote its eﬀect
on insulin sensitivity and help improving metabolic proﬁle of PCOS
patients (Karakas et al., 2016; Newgard, 2012).
4.2. Eﬀect on clinical symptoms
Women with PCOS experience mood dysfunction and psychiatric
problems (Farrell and Antoni, 2010) which are commonly depression
and anxiety and mostly related to the discomfort associated with dis-
ease presentation including hirsutism, acne, obesity and subfertility
(Barry et al., 2011). We found that the co-administration of vitamin D
and omega-3 fatty acid to women with PCOS for 12 weeks improved
mental and general health presented by signiﬁcant reduction in BDI,
GHQ and DASS scores compared with the placebo. Our results were
consistent with others showing that high dose vitamin D supple-
mentation ameliorates depressive symptoms in participants suﬀering
from depression (Jorde et al., 2008; Vieth et al., 2007). There are
Fig. 2. Eﬀect of the 12-week supplementation with Vitamin D plus omega-3 or placebo on expression ratio of IL-1, IL-8 and TNF-α gene in blood mononuclear cells of
PCOS women.
Fig. 3. Eﬀect of the 12-week supple-
mentation with Vitamin D plus omega-
3 or placebo on expression ratio of
TGF-β and VEGF gene in blood mono-
nuclear cells of PCOS women. IL-1, in-
terleukin-1; IL-8, interleukin-8; PCOS,
polycystic ovary syndrome; TNF-α,
tumor necrosis factor alpha; TGF-β,
transforming growth factor beta; VEGF,
vascular endothelial growth factor.
Table 4
Adjusted changes in metabolic proﬁle of patients with polycystic ovary syn-
drome.
Placebo group
(n=30)
Vitamin D plus omega-
3 group (n=30)
P1
25-OH-vitamin D (ng/mL) 0.2 ± 0.7 9.9 ± 0.7 <0.001
Total testosterone (ng/mL) 0.1 ± 0.1 −0.1 ± 0.1 0.02
SHBG (nmol/L) 4.5 ± 4.2 5.8 ± 4.2 0.83
FAI% −0.02 ± 0.01 −0.03 ± 0.01 0.67
mF-G scores −0.2 ± 0.1 −0.4 ± 0.1 0.14
BDI total scores −0.5 ± 0.2 −1.4 ± 0.2 0.006
GHQ scores −1.7 ± 0.6 −4.8 ± 0.6 0.001
DASS scores −2.1 ± 0.8 −5.2 ± 0.8 0.01
hs-CRP (mg/L) 0.2 ± 0.1 −0.5 ± 0.1 <0.001
NO (μmol/L) −1.1 ± 1.1 −0.1 ± 1.1 0.50
TAC (mmol/L) −11.4 ± 27.0 123.5 ± 27.0 0.001
GSH (μmol/L) 18.2 ± 17.9 −9.5 ± 17.9 0.28
MDA (μmol/L) 0.2 ± 0.1 −0.4 ± 0.1 <0.001
All values are means ± SEs. Values are adjusted for baseline values, age and
BMI at baseline.
BDI, beck depression inventory; DASS, depression anxiety and stress scale;
GHQ, general health questionnaire; GSH, total glutathione; FAI, free androgen
index; hs-CRP, high-sensitivity C-reactive protein; mF-G, modiﬁed Ferriman
Gallwey; MDA, malondialdehyde; NO, nitric oxide; SHBG, sex hormone-binding
globulin; TAC, total antioxidant capacity.
1 Obtained from ANCOVA.
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several mechanisms explaining the impact of vitamin D on brain
function including its direct eﬀect on brain and serotonin uptake
through vitamin D receptors distributed all over the brain
(Stumpf et al., 1982), vitamin D indirect impact through its function of
improving muscle strength which increases physical activity and gen-
eral health (Bischoﬀ-Ferrari et al., 2006) and its eﬀect on decreasing
PTH level which is inversely associated with brain function
(Smogorzewski, 2001). In addition, unsaturated fatty acids such as
omega-3 are highly distributed in neural phospholipids, the major
component of the neuronal cell membrane. Omega-3 fatty acid might
modulate dopaminergic and serotonergic pathways which are essential
for proper brain function (Bozzatello et al., 2016). The combination of
vitamin D and omega-3 fatty acid might enhance serotonin synthesis,
release, and function in the brain.
4.3. Eﬀect on inﬂammation and oxidative stress
Current evidence suggest that chronic inﬂammation resulted from
abdominal obesity and adipose tissue dysfunction in PCOS patients is
involved in the development of complex features of PCOS including
dyslipidemia, insulin resistance, T2DM, cardiovascular risk factors,
hyperandrogenism and anovulation (Nasiri et al., 2015; Spritzer et al.,
2015). Inﬂammation in these patients might contribute to atherogenesis
in PCOS (Gonzalez et al., 2012). Oxidative stress, presented as in-
creased level of MDA and suppressed TAC, is considered as a possible
pathophysiology for PCOS. Our ﬁndings documented that vitamin D
and omega-3 fatty acid co-supplementation for 12 weeks signiﬁcantly
decreased serum hs-CRP and plasma MDA levels and gene expression of
IL-1 as well as increased plasma TAC level among patients with PCOS.
We also found out that the gene expression of VEGF was upregulated in
women with PCOS, following the co-administration of vitamin D and
omega-3 fatty acid for 12 weeks, which was not consistent with
Irani et al. (2015) and Gruber et al. (2008), demonstrating decreased
levels of VEGF following vitamin D supplementation. Our study did not
show any eﬀect of combined vitamin D and omega-3 on plasma NO,
GSH, and gene expression related to IL-8, TNF-α and TGF-β. VEGF is a
regulator of angiogenesis though its alteration might be involved in
diﬀerent pathologies such as preeclampsia, renal disease and PCOS
(Tal et al., 2015). There is controversy regarding the eﬀect of vitamin D
supplementation on VEGF gene expression. Women with PCOS usually
produce more VEGF associated with increased vascularity which might
increase the risk of ovarian hyperstimulation syndrome following fol-
licular stimulation, though improves tissue oxygenation boosts immune
system in its moderate levels (Zaidi et al., 1995). The discrepancy be-
tween what we found in the current study and other clinical trials
showing the negative association between vitamin D status and VEGF
levels might be related to vitamin D supplementation dose and/or
duration of intervention and other medical conditions might inﬂuence
their relationship. Chronic diseases are usually better managed through
multi-nutrients administration and improving overall nutritional status.
Combining vitamin D and omega-3 fatty acid in women with PCOS
produced better results because vitamin D intake improves oxidative
stress through its antioxidant activities (Cetinkalp et al., 2009) and
reducing the production of reactive oxygen species and pro-in-
ﬂammatory cytokines (Jain and Micinski, 2013), and omega-3 fatty
acid with its anti-inﬂammatory properties ameliorates oxidative stress
(Hassan Eftekhari et al., 2013).
4.4. Limitations
The main limitation of this trial was that the circulating levels of
free fatty acids were not been measured. We did not evaluate the eﬀects
of vitamin D and omega-3 fatty acids co-supplementation on gene ex-
pression related to oxidative stress and metabolic proﬁles. In addition, a
small sample size, short duration of intervention, small doses of sup-
plement and serum vitamin status at the beginning of the intervention
may aﬀect our ﬁndings. Therefore, these should be taken into account
in the interpretation of our ﬁndings.
4.5. Conclusions
Overall, the co-administration of vitamin D and omega-3 fatty acid
for 12 weeks had beneﬁcial eﬀects on mental health status, total tes-
tosterone level, serum hs-CRP, plasma TAC and MDA levels, and gene
expression of IL-1 and VEGF among women suﬀering from PCOS. Our
ﬁndings support the anti-inﬂammatory and immunomodulatory roles of
combined vitamin D and omega-3 supplementation.
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